Scientific research progress of COVID-19/SARS-CoV-2 in the first five months
Open Access
- 1 June 2020
- journal article
- review article
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 24 (12), 6558-6570
- https://doi.org/10.1111/jcmm.15364
Abstract
A cluster of pneumonia (COVID-19) cases have been found in Wuhan China in late December, 2019, and subsequently, a novel coronavirus with a positive stranded RNA was identified to be the aetiological virus (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2), which has a phylogenetic similarity to severe acute respiratory syndrome coronavirus (SARS-CoV). SARS-CoV-2 transmits mainly through droplets and close contact and the elder or people with chronic diseases are high-risk population. People affected by SARS-CoV-2 can be asymptomatic, which brings about more difficulties to control the transmission. COVID-19 has become pandemic rapidly after onset, and so far the infected people have been above 2 000 000 and more than 130 000 died worldwide according to COVID-19 situation dashboard of World Health Organization (). Here, we summarized the current known knowledge regarding epidemiological, pathogenesis, pathology, clinical features, comorbidities and treatment of COVID-19/ SARS-CoV-2 as reference for the prevention and control COVID-19.Funding Information
- National Natural Science Foundation of China (81521001, 81870182)
This publication has 113 references indexed in Scilit:
- Epidemiology, Genetic Recombination, and Pathogenesis of CoronavirusesTrends in Microbiology, 2016
- Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocolSpringerPlus, 2015
- Interhuman transmissibility of Middle East respiratory syndrome coronavirus: estimation of pandemic riskThe Lancet, 2013
- Apilimod Inhibits the Production of IL-12 and IL-23 and Reduces Dendritic Cell Infiltration in PsoriasisPLOS ONE, 2012
- Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus InfectionClinical Infectious Diseases, 2011
- IgM in microbial infections: Taken for granted?Immunology Letters, 2009
- The spike protein of SARS-CoV — a target for vaccine and therapeutic developmentNature Reviews Microbiology, 2009
- Inhibition of the interaction between the SARS-CoV Spike protein and its cellular receptor by anti-histo-blood group antibodiesGlycobiology, 2008
- Use of convalescent plasma therapy in SARS patients in Hong KongEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004
- Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS‐CoV) in SARS patients: implications for pathogenesis and virus transmission pathwaysThe Journal of Pathology, 2004